Abstract Number: PB0260
Meeting: ISTH 2021 Congress
Theme: COVID and Coagulation » COVID and Coagulation, Clinical
Background: The clinical course of severe respiratory syndrome Coronavirus 2 (SARS-CoV-2) in persons with haemophilia (PWH) and other congenital bleeding disorders (CBD) is not fully recognized despite worldwide spread of the disease.
Aims: The study aim was to describe the clinical course of COVID-19 in PWH and other CBD.
Methods: Between October 2020 and February 2021 we identified 28 cases of Coronavirus Disease 2019 (COVID-19) among PWH and other CBD treated in our Centre. COVID-19 was PCR confirmed in all.
Results: Of 28 patients aged 19-76 (median 46) enrolled in the study, 17 (61%) had severe haemophilia A [5 with factor (F) VIII inhibitor], 3 – non-severe haemophilia A, 1 – severe haemophilia B, 5 – von Willebrand Disease, 1 – FVII deficiency, 1 – hypofibrinogenemia. At COVID-19 diagnosis the underlying bleeding disorder was treated with long-term prophylaxis in 18/28 (64%) patients (the remaining patients were treated on-demand). Conditions/comorbidities that put our study patients at higher risk of severe COVID-19 were arterial hypertension (11/28, 39%), diabetes mellitus (3/28, 11%), obesity (5/28, 18%). COVID-19 was mild in 27/28 (96%) patients who required no hospitalization. For those patients no changes in therapy of underlying bleeding disorder were introduced with 5 exceptions:prophylaxis was intensified (n=2), reduced (n=2) or temporarily discontinued (n=1). One severe haemophilia A patient without FVIII inhibitor (obese, arterial hypertension) required hospitalization in ICU for respiratory failure. He received low-molecular weight heparin for thromboprophylaxis (half therapeutic dose) with daily FVIII (35 IU/kg) replacement with no bleeding/thrombotic complications. All patients recovered with no bleeding/thrombotic complications. Several weeks after recovery from COVID-19 cardiac arrhythmia was identified In 2 patients.
Conclusions: The course of COVID-19 in most patients with haemophilia and allied disorders was mild with no significant impact on the therapy of the underlying bleeding disorder.
To cite this abstract in AMA style:
Sikorska A, Stefanska-Windyga E, Windyga J. Clinical Course of COVID-19 in Patients with Inherited Bleeding Disorders: An Interim Analysis of 28 Cases [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/clinical-course-of-covid-19-in-patients-with-inherited-bleeding-disorders-an-interim-analysis-of-28-cases/. Accessed December 6, 2021.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/clinical-course-of-covid-19-in-patients-with-inherited-bleeding-disorders-an-interim-analysis-of-28-cases/